LabCorp Diagnostics was down 2.8 percent, while Covance Drug Development was up 8 percent. The firm narrowed its revenue and earnings guidance for the year.
Clinical Pathology Laboratories said information on 2.2 million patients had been exposed in the same data breach that impacted millions of Quest and LabCorp patients.
With two FDA-cleared platforms available, the technology is drawing clinicians interested in reaping its near-term benefits while preparing for its future impact.
The anticipated shortage for clinics comes at a time when more clinicians are already switching to lab-based IGRA testing, diagnostic industry executives said.
The center will initially use the system for prostate, and head and neck cancers and in the future will let LabCorp patients access Mount Sinai pathologists.
About 200,000 LabCorp patients may have had their credit card or bank information improperly accessed by the breach, which also hit 11.9 million Quest patients.
Proceeds from the loan facility will go toward the acquisition of Envigo's nonclinical research services business and other general corporate purposes.
The financing accelerates the development of the Zero Delay plasma preparation system for immediate blood plasma isolation and stabilization at the point of collection.
While the impact on participants' bottom lines remains to be seen, some lab company leaders said they expect to see other payors explore similar plans.